{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:06:25Z","timestamp":1749182785706,"version":"3.41.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Traditionally, systemic therapy based on androgen deprivation therapy (ADT) has been the primary approach for treating metastatic prostate cancer. Local therapies targeting metastatic lesions have rarely been employed for cancer control. However, the advent of next-generation imaging modalities, such as choline positron emission tomography (PET), whole-body magnetic resonance imaging, and prostate-specific membrane antigen (PSMA)-PET, has enabled the detection of oligometastases that were previously undetectable using conventional imaging techniques, such as computed tomography and bone scintigraphy. This has led to increased attention to local therapy for oligometastatic prostate cancer with cancer control. Oligometastatic prostate cancer can be classified into three categories: de novo oligometastases (oligometastases identified at initial diagnosis), oligorecurrence (oligometastases arising after radical treatment of primary tumor), and oligoprogression (activation of oligometastases following ADT failure). Evidence from randomized controlled trials (RCTs) supports the efficacy of local therapy in these contexts. The phase III STAMPEDE trial demonstrated that the addition of prostate radiotherapy to ADT improved the overall survival in patients with de novo low-volume metastatic prostate cancer. Furthermore, in the STOMP and ORIOLE trials, phase II RCTs have shown that metastasis-directed therapy significantly prolongs progression-free survival (PFS) in patients with oligorecurrent prostate cancer after radical treatment. For oligoprogressive castration-resistant prostate cancer, the phase II ARTO trial demonstrated that the addition of radiotherapy targeting oligometastases to first-line abiraterone acetate and prednisone treatments improved PFS. With the global adoption of PSMA-PET, local therapy for primary tumor and metastases in oligometastatic prostate cancer is expected to play an increasingly prominent role in the future.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf048","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T16:41:41Z","timestamp":1742056901000},"page":"571-577","source":"Crossref","is-referenced-by-count":0,"title":["Local therapy for oligometastatic prostate cancer"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-2874","authenticated-orcid":false,"given":"Taketo","family":"Kawai","sequence":"first","affiliation":[{"name":"Department of Urology, International University of Health and Welfare Ichikawa Hospital , 6-1-14 Konodai, Ichikawa, Chiba 272-0827 ,","place":["Japan"]},{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-4294","authenticated-orcid":false,"given":"Satoru","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University School of Medicine , 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"2025060506414342900_ref1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1200\/EDBK_239041","article-title":"Oligometastatic prostate cancer: A shrinking subset or an opportunity for cure?","volume":"39","author":"Rao","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025060506414342900_ref2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5306\/wjco.v10.i2.38","article-title":"Oligometastases in prostate cancer: Ablative treatment","volume":"10","author":"Palacios-Eito","year":"2019","journal-title":"World J Clin Oncol"},{"key":"2025060506414342900_ref3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"2025060506414342900_ref4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: Reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"key":"2025060506414342900_ref5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of Patients with advanced prostate cancer: Report of the advanced prostate cancer consensus conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"key":"2025060506414342900_ref6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"key":"2025060506414342900_ref7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: Meta-analysis and critical review of available data","volume":"43","author":"Fanti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060506414342900_ref8","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.ejrad.2012.04.027","article-title":"Role of 11C-choline PET\/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy","volume":"81","author":"Fuccio","year":"2012","journal-title":"Eur J Radiol"},{"key":"2025060506414342900_ref9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skeletal Radiol"},{"key":"2025060506414342900_ref10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MNM.0000000000000040","article-title":"Meta-analysis of (11)C-choline and (18)F-choline PET\/CT for management of patients with prostate cancer","volume":"35","author":"Eyben","year":"2014","journal-title":"Nucl Med Commun"},{"key":"2025060506414342900_ref11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/pros.22921","article-title":"Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer","volume":"75","author":"Pinaquy","year":"2015","journal-title":"Prostate"},{"key":"2025060506414342900_ref12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00259-013-2634-1","article-title":"Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography\/computed tomography for preoperative lymph node staging in prostate cancer patients","volume":"41","author":"Heck","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060506414342900_ref13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.eururo.2011.01.015","article-title":"Prospective evaluation of 11C-choline positron emission tomography\/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases","volume":"60","author":"Budiharto","year":"2011","journal-title":"Eur Urol"},{"key":"2025060506414342900_ref14","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.urolonc.2014.11.008","article-title":"Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement","volume":"33","author":"Van den Bergh","year":"2015","journal-title":"Urol Oncol"},{"key":"2025060506414342900_ref15","first-page":"275","article-title":"Diffusion weighted whole body imaging with background body signal suppression (DWIBS): Technical improvement using free breathing, STIR and high resolution 3D display","volume":"22","author":"Takahara","year":"2004","journal-title":"Radiat Med"},{"key":"2025060506414342900_ref16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00256-009-0789-4","article-title":"Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma","volume":"39","author":"Gutzeit","year":"2010","journal-title":"Skeletal Radiol"},{"key":"2025060506414342900_ref17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","article-title":"Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?","volume":"62","author":"Lecouvet","year":"2012","journal-title":"Eur Urol"},{"key":"2025060506414342900_ref18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"2025060506414342900_ref19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"(68)Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA &lt;0.5 ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060506414342900_ref20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","article-title":"(68)Ga-PSMA-11 PET\/CT in recurrent prostate cancer: Efficacy in different clinical stages of PSA failure after radical therapy","volume":"46","author":"Ceci","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060506414342900_ref21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","article-title":"Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy","volume":"73","author":"Rauscher","year":"2018","journal-title":"Eur Urol"},{"key":"2025060506414342900_ref22","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00259-019-04385-6","article-title":"Early lesion detection with 18F-DCFPyL PET\/CT in 248 patients with biochemically recurrent prostate cancer","volume":"46","author":"Wondergem","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060506414342900_ref23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00259-017-3818-x","article-title":"Clinical impact of PSMA-based (18)F-DCFBC PET\/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy","volume":"45","author":"Mena","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060506414342900_ref24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"2025060506414342900_ref25","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"2025060506414342900_ref26","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"2025060506414342900_ref27","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"2025060506414342900_ref28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"volume-title":"Prostate cancer","author":"EAU Guidelines","key":"2025060506414342900_ref29"},{"volume-title":"Prostate cancer. Version 1","year":"2025","author":"NCCN Clinical Practice Guidelines in Oncology","key":"2025060506414342900_ref30"},{"key":"2025060506414342900_ref31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bju.15669","article-title":"Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: The testing radical prostatectomy in men with prostate cancer and oligo-metastases to the bone (TRoMbone) trial","volume":"130","author":"Sooriakumaran","year":"2022","journal-title":"BJU Int"},{"key":"2025060506414342900_ref32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed Oligometastatic prostate cancer: A phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2025060506414342900_ref33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","article-title":"The role of Cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the local treatment of metastatic prostate cancer (LoMP) registry","volume":"29","author":"Lumen","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"2025060506414342900_ref34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bju.15553","article-title":"Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study)","volume":"129","author":"Buelens","year":"2022","journal-title":"BJU Int"},{"key":"2025060506414342900_ref35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41391-023-00752-5","article-title":"Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review","volume":"27","author":"Saouli","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025060506414342900_ref36","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for Oligometastatic prostate cancer recurrence: A prospective, randomized, Multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025060506414342900_ref37","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for Oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025060506414342900_ref38","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in Oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025060506414342900_ref39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-020-06911-4","article-title":"PEACE V - salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): A study protocol for a randomized controlled phase II trial","volume":"20","author":"De Bruycker","year":"2020","journal-title":"BMC Cancer"},{"key":"2025060506414342900_ref40","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s11255-020-02762-x","article-title":"Genuine- and induced-oligometastatic castration-resistant prostate cancer: Clinical features and clinical outcomes after progressive site-directed therapy","volume":"53","author":"Yoshida","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"2025060506414342900_ref41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.prnil.2023.10.002","article-title":"Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer","volume":"11","author":"Kawai","year":"2023","journal-title":"Prostate Int"},{"key":"2025060506414342900_ref42","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.eururo.2018.11.050","article-title":"Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease?","volume":"75","author":"Lohaus","year":"2019","journal-title":"Eur Urol"},{"key":"2025060506414342900_ref43","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1007\/s00259-021-05298-z","article-title":"Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET\/CT in castration-resistant prostate cancer patients","volume":"48","author":"Onal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060506414342900_ref44","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ijrobp.2019.06.011","article-title":"Progressive site-directed therapy for castration-resistant prostate cancer: Localization of the progressive site as a prognostic factor","volume":"105","author":"Yoshida","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025060506414342900_ref45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/iju.15090","article-title":"Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy","volume":"30","author":"Yoshida","year":"2023","journal-title":"Int J Urol"},{"key":"2025060506414342900_ref46","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s11255-019-02233-y","article-title":"Carbon 11-choline positron emission tomography\/computed tomography and palliative local therapy for castration-resistant prostate cancer","volume":"51","author":"Nozaki","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"2025060506414342900_ref47","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s00345-019-02717-7","article-title":"Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: A multicenter study","volume":"37","author":"Triggiani","year":"2019","journal-title":"World J Urol"},{"key":"2025060506414342900_ref48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.euo.2019.08.012","article-title":"Progression-directed therapy for Oligoprogression in castration-refractory prostate cancer","volume":"4","author":"Berghen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2025060506414342900_ref49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in Oligoprogressive castration-resistant prostate cancer","volume":"4","author":"Deek","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2025060506414342900_ref50","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and Abiraterone acetate for patients affected by Oligometastatic castrate-resistant prostate cancer: A randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025060506414342900_ref51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12894-023-01202-z","article-title":"A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)","volume":"23","author":"Yoshida","year":"2023","journal-title":"BMC Urol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/6\/571\/62418536\/hyaf048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/6\/571\/62418536\/hyaf048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T10:41:51Z","timestamp":1749120111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/6\/571\/8079043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3,15]]},"published-print":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf048","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,15]]}}}